MX2020009544A - Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada. - Google Patents

Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada.

Info

Publication number
MX2020009544A
MX2020009544A MX2020009544A MX2020009544A MX2020009544A MX 2020009544 A MX2020009544 A MX 2020009544A MX 2020009544 A MX2020009544 A MX 2020009544A MX 2020009544 A MX2020009544 A MX 2020009544A MX 2020009544 A MX2020009544 A MX 2020009544A
Authority
MX
Mexico
Prior art keywords
treatment
antibodies
pustular psoriasis
generalized pustular
generalized
Prior art date
Application number
MX2020009544A
Other languages
English (en)
Spanish (es)
Inventor
Steven John Padula
Janine Lamar
Christian Thoma
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2020009544A publication Critical patent/MX2020009544A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2020009544A 2018-03-14 2019-03-08 Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada. MX2020009544A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862642641P 2018-03-14 2018-03-14
US201862683720P 2018-06-12 2018-06-12
US201862699274P 2018-07-17 2018-07-17
US201862729518P 2018-09-11 2018-09-11
PCT/US2019/021335 WO2019177888A1 (en) 2018-03-14 2019-03-08 Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis

Publications (1)

Publication Number Publication Date
MX2020009544A true MX2020009544A (es) 2020-10-05

Family

ID=65904556

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009544A MX2020009544A (es) 2018-03-14 2019-03-08 Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada.

Country Status (13)

Country Link
US (2) US20190284285A1 (https=)
EP (1) EP3765513A1 (https=)
JP (2) JP7404256B2 (https=)
KR (1) KR102768040B1 (https=)
CN (1) CN112272674A (https=)
AU (1) AU2019236105B2 (https=)
BR (1) BR112020016738A2 (https=)
CA (1) CA3093692A1 (https=)
CL (1) CL2020002342A1 (https=)
IL (1) IL277215B2 (https=)
MX (1) MX2020009544A (https=)
PH (1) PH12020551444A1 (https=)
WO (1) WO2019177888A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
EP3902604A1 (en) * 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
BR112021016198A2 (pt) * 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
EP4182022A1 (en) * 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
WO2022026829A1 (en) * 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
JP2023536851A (ja) * 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
CN121324515A (zh) * 2020-09-16 2026-01-13 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
US20220119538A1 (en) * 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
WO2022192531A2 (en) * 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂
CN115327130A (zh) * 2022-07-25 2022-11-11 深圳市妇幼保健院 一种免疫生物标志物在制备小儿脓毒血症诊断试剂盒中的应用
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
ES2274574T3 (es) 1997-08-01 2007-05-16 Schering Corporation Proteinas de membrana celular de mamifero; reactivos relacionados.
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
DE19733389C2 (de) 1997-08-01 1999-08-19 Deutsches Krebsforsch Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP1627927A3 (en) 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
EP1556403A4 (en) 2002-10-03 2006-06-28 Large Scale Biology Corp MAKING MULTIMETER PROTEINS
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1977007A4 (en) * 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
MX2009002456A (es) 2006-09-08 2009-03-20 Amgen Inc Variantes de la familia il-1.
CA2685015A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
US20100221252A1 (en) 2007-06-29 2010-09-02 Schering Corporation Mdl-1 uses
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
US9124378B2 (en) 2007-10-06 2015-09-01 The Nielsen Company (Us), Llc Gathering research data
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
WO2011026948A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
HRP20181598T1 (hr) 2010-06-03 2018-11-30 Abbvie Biotechnology Ltd Uporaba i pripravci za liječenje hidradenitis suppurativa (hs)
KR102038310B1 (ko) * 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
EP4223312A1 (en) * 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
DK3194583T3 (da) 2014-07-30 2021-12-20 Zumutor Biologics Inc Ikke-fucosyleret protein og fremgangsmåder dermed
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CN107660155B (zh) 2015-04-24 2021-02-02 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
CN106470162B (zh) 2015-08-19 2019-06-25 中国移动通信集团公司 一种业务报文的组播方法及装置
JP6654773B2 (ja) 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CN107362351B (zh) 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
AU2019234478A1 (en) 2018-03-14 2020-08-20 Boehringer Ingelheim International Gmbh Use of anti-IL36R antibodies for treatment of inflammatory bowel disease
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
IL278267B2 (en) 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
EP3902604A1 (en) 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
KR102708558B1 (ko) 2019-06-20 2024-09-24 삼성전자주식회사 수직형 메모리 장치
WO2021087245A1 (en) 2019-10-30 2021-05-06 The Texas A&M University System Protease switch for dual targets chimeric antigen receptor t cell therapy
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
US20220119538A1 (en) 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain

Also Published As

Publication number Publication date
IL277215A (en) 2020-10-29
IL277215B1 (en) 2025-06-01
CL2020002342A1 (es) 2020-12-18
CN112272674A (zh) 2021-01-26
BR112020016738A2 (pt) 2020-12-15
AU2019236105B2 (en) 2025-07-31
JP2021517566A (ja) 2021-07-26
JP2024028951A (ja) 2024-03-05
AU2019236105A1 (en) 2020-08-27
WO2019177888A1 (en) 2019-09-19
IL277215B2 (en) 2025-10-01
CA3093692A1 (en) 2019-09-19
PH12020551444A1 (en) 2021-08-23
JP7404256B2 (ja) 2023-12-25
KR20200131871A (ko) 2020-11-24
US12503512B2 (en) 2025-12-23
US20190284285A1 (en) 2019-09-19
EP3765513A1 (en) 2021-01-20
US20210087285A1 (en) 2021-03-25
JP7673168B2 (ja) 2025-05-08
KR102768040B1 (ko) 2025-02-17

Similar Documents

Publication Publication Date Title
PH12020551444A1 (en) Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
PH12019502283A1 (en) Anti-lag3 antibodies
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
EA202091540A1 (ru) Антитела к lilrb2
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
PH12017502342B1 (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
EP4461312A3 (en) Anti-pro/latent-myostatin antibodies and uses thereof
MY193661A (en) Anti-tim3 antibodies and methods of use
EP4613332A3 (en) Cot modulators and methods of use thereof
MY205689A (en) Antibody molecules to cd138 and uses thereof
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MY205583A (en) Acid-alpha glucosidase variants and uses thereof
MX2019008029A (es) Anticuerpo anti-alfa-sinucleina y su uso.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
GB2540702A (en) Nucleic acid processing of a nucleic acid fragment with a triazole linkage
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
EP4487912A3 (en) Improved treatment of atopic dermatitis with tradipitant
MX2017007970A (es) Uso de una molécula de unión que se une específicamente al precursor del factor neurotrófico derivado del cerebro.